Exendin-4 modulates diabetes onset in nonobese diabetic mice.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Endocrinology

• Publication date

  2008-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/EN.2007-1137PMID 18063685PMCID PMC2275367
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Continuous stimulation of human glucagon-like peptide-1 (7–36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes

  2007influential reference
• Effect of Exenatide on &bgr; Cell Function After Islet Transplantation in Type 1 Diabetes

  2007cited by this paper
• Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.

  2007cited by this paper
• Attenuation of type 2 diabetes mellitus in the male Zucker diabetic fatty rat: the effects of stress and non-volitional exercise.

  2007cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006influential reference
• Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes.

  2006cited by this paper
• Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes.

  2006cited by this paper
• International trial of the Edmonton protocol for islet transplantation.

  2006cited by this paper
• Therapeutic approaches to preserve islet mass in type 2 diabetes.

  2006cited by this paper
• Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

  2005cited by this paper
• Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion.

  2005cited by this paper
• Impaired Post-Thymic Development of Regulatory CD4+25+ T Cells Contributes to Diabetes Pathogenesis in BB Rats1

  2005cited by this paper
• Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B

  2005cited by this paper
• Glucagon-like peptide-1 prevents beta cell glucolipotoxicity

  2004cited by this paper
• Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.

  2004influential reference
• Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells

  2004cited by this paper
• Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis*

  2003cited by this paper
• Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.

  2003cited by this paper
• Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis.

  2003cited by this paper
• Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

  2002cited by this paper
• Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

  2000cited by this paper
• Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice.

  2000cited by this paper
• Two genetic loci regulate T cell-dependent islet inflammation and drive autoimmune diabetes pathogenesis.

  2000cited by this paper
• Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

  1999cited by this paper
• IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice.

  1997cited by this paper
• Glucagon-like-peptide-1 (7–36) amide improves glucose sensitivity in beta-cells of NOD mice

  1996cited by this paper
• Protection of nonobese diabetic mice from autoimmune diabetes by reduction of islet mass before insulitis.

  1996cited by this paper
• Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM

  1995cited by this paper
• Histological study of pancreatic beta-cell loss in relation to the insulitis process in the non-obese diabetic mouse

  1994cited by this paper
• Course of pancreatic beta cell destruction in prediabetic NOD mice: a histomorphometric evaluation.

  1994cited by this paper
• Polygenic Nature of Spontaneous Diabetes in the Rat: Permissive MHC Haplotype and Presence of the Lymphopenic Trait of the BB Rat Are Not Sufficient to Produce Susceptibility

  1992cited by this paper
• First phase insulin release in the non-obese diabetic mouse: correlation with insulitis, beta cell number and autoantibodies.

  1992cited by this paper
• Early nicotinamide treatment in the NOD mouse: effects on diabetes and insulitis suppression and autoantibody levels.

  1990cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper

• Messenger RNA delivery to islet β cells using conjugated lipid nanoparticles.

  2026cites this paper
• Recent progress of remission in type 2 diabetes

  2025cites this paper
• Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes

  2025cites this paper
• Treatment with sitagliptin exacerbates the M2 phenotype in macrophages in vitro.

  2024cites this paper
• Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule.

  2024cites this paper
• Targeting the Autoreactive CD8 T-cell Receptor in Type 1 Diabetes: Insights from scRNA-seq for Immunotherapy.

  2024cites this paper
• Semaglutide decelerates the growth and progression of breast cancer by enhancing the acquired antitumor immunity.

  2024cites this paper
• An update on pancreatic regeneration mechanisms: Searching for paths to a cure for type 2 diabetes

  2023cites this paper
• Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice

  2022cites this paper
• Exendin-4 Exacerbates Burn-Induced Mortality in Mice by Switching to Th2 Response.

  2022cites this paper
• INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6‐month treatment with incretin‐based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double‐blind, randomised controlled trials (INVESTDIA)

  2022cites this paper
• Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.

  2022cites this paper
• GLP-1 receptor agonist as a modulator of innate immunity

  2022cites this paper
• The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.

  2022cites this paper
• Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis

  2021cites this paper
• The role of incretins and incretin-based drugs in autoimmune diseases.

  2021cites this paper
• Next-gen therapeutics to spare and expand beta-cell mass.

  2021cites this paper
• Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

  2020cites this paper
• Changes in the transcriptional activity of the entero-insular axis genes in streptozotocin-induced diabetes and after the administration of TNF-α non-selective blockers

  2020cites this paper
• GLP-1R is downregulated in beta cells of NOD mice and T1D patients

  2019cites this paper
• Exendin-4 Exacerbates Burn-Induced Morbidity in Mice by Activation of the Sympathetic Nervous System

  2019influential citation
• Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues

  2019cites this paper
• PAHSAs attenuate immune responses and promote β cell survival in autoimmune diabetic mice.

  2019influential citation
• Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus

  2019cites this paper
• Glucagon Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T Cell Proliferation.

  2019cites this paper
• Improved β-cell Function and Prolonged Remission of Diabetes Type 1 by GLP-1 Agonist Treatment in Newly Diagnosed Adolescences

  2019cites this paper
• DPP-4 Inhibition Leads to Decreased Pancreatic Inflammatory Profile and Increased Frequency of Regulatory T Cells in Experimental Type 1 Diabetes

  2019cites this paper
• GABAergic regulation of pancreatic islet cells: Physiology and antidiabetic effects

  2019cites this paper
• Exendin‐4 overcomes cytokine‐induced decreases in gap junction coupling via protein kinase A and Epac2 in mouse and human islets

  2018cites this paper
• Exendin‐4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant

  2018cites this paper
• Vildagliptin/pioglitazone combination improved the overall glycemic control in type I diabetic rats.

  2018cites this paper
• Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents Beta Cell Damage and Promotes Beta Cell Regeneration in Mice

  2017cites this paper
• Complete loss of insulin secretion capacity in type 1A diabetes patients during long‐term follow up

  2017cites this paper
• Liraglutide Enhances the Efficacy of Human Mesenchymal Stem Cells in Preserving Islet ß-cell Function in Severe Non-obese Diabetic Mice

  2016cites this paper
• Never Waste a Good Crisis: Confronting Reproducibility in Translational Research.

  2016cites this paper
• The effect of Exendin-4 on apoptosis of islet cells in rats with type I diabetes

  2016cites this paper
• Effects of Exendin-4 and Antioxidants on Adult Diabetic Male Albino Rats = تأثير عقار إكزندين-4 ومضادات الأكسدة على ذكور الجرذان البيضاء المصابة بالداء السكري

  2016cites this paper
• Post-Bariatric Surgery Hypoglycemia

  2016cites this paper
• Hyperglucagonemia in an animal model of insulin- deficient diabetes: what therapy can improve it?

  2016cites this paper
• GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?

  2015cites this paper
• Inkretin-basierte Therapie: ein ergänzender Therapieansatz bei Patienten mit Typ-1-Diabetes?

  2015cites this paper
• GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7.

  2015cites this paper
• Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation, Jyuhn-Huarng

  2015cites this paper
• Post-Gastric Bypass Hyperinsulinemic Hypoglycemia: Fructose is a Carbohydrate Which Can Be Safely Consumed.

  2015cites this paper
• GLP-1-Exendin-4/IgG4 (Fc) fusion protein as a novel drug for diabetes treatment.

  2015cites this paper
• Pro-GLP-1, a Pro-drug of GLP-1, is neuroprotective in cerebral ischemia.

  2015cites this paper
• Current Approaches and Future Prospects for the Prevention of β-Cell Destruction in Autoimmune Diabetes

  2015cites this paper
• Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice.

  2014cites this paper
• A fusion protein derived from plants holds promising potential as a new oral therapy for type 2 diabetes.

  2014cites this paper
• Benefits of healthy adipose tissue in the treatment of diabetes.

  2014cites this paper
• The role of incretin-based therapies in prediabetes: a review.

  2014cites this paper
• Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus.

  2014cites this paper
• Anti-inflammatory role of GLP-1 and the effect of gastric bypass on diabetes- and obesity-associated inflammation

  2014cites this paper
• Loss of Pgc-1α expression in aging mouse muscle potentiates glucose intolerance and systemic inflammation.

  2014cites this paper
• An overview of non-insulin adjunctive therapies for Type 1 diabetes

  2014cites this paper
• Hypoglycemia after Roux-en-Y Gastric Bypass Surgery

  2014cites this paper
• Effects of all-trans retinoid acid and exendin-4 on islet transplantation in NOD mice.

  2014cites this paper
• Prevention and Reversal of Diabetes by All-Trans Retinoid Acid and Exendin-4 in NOD Mice

  2014cites this paper
• Immunotherapeutic treatment of autoimmune diabetes.

  2013cites this paper
• The effects of DPP-IV inhibition in NOD mice with overt diabetes.

  2013cites this paper
• Increased expression of glucagon‐like peptide‐1 receptors in psoriasis plaques

  2013cites this paper
• The Effects of DPP-IV Inhibition in NOD Mice with Overt Diabetes (type1diabetes/sitagliptin/NODmice/regulatoryTcells/DPP-IV)

  2013cites this paper
• Loss of Pgc-1α Expression in Aging Mouse Muscle Potentiates Glucose Intolerance and 1 Systemic Inflammation 2 3 Divs. of Cardiovascular and Metabolic Disease And

  2013cites this paper
• GLP-1 agonists in type 1 diabetes.

  2013cites this paper
• Anti‐inflammatory effects of exendin‐4, a glucagon‐like peptide‐1 analog, on human peripheral lymphocytes in patients with type 2 diabetes

  2013cites this paper
• Evaluation of Hypoglycemic and Antioxidative Effects of Synthesized Peptide MC62

  2013cites this paper
• GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.

  2013cites this paper
• Functional activity of murine intestinal mucosal cells is regulated by the glucagon-like peptide-1 receptor.

  2013cites this paper
• The gut-brain axis in the critically ill: Is glucagon-like peptide-1 protective in neurocritical care?

  2013cites this paper
• Pharmacology, physiology, and mechanisms of incretin hormone action.

  2013influential citation
• Production of bioactive metabolites by intestinal bacteria

  2013cites this paper
• Incretins: new targets for the prevention of diabetes and obesity

  2013cites this paper
• Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.

  2012cites this paper
• β-cell mass in non-obese diabetic NOD mice

  2012cites this paper
• The DPP 4 inhibitor linagliptin dela ys the onset of diabetes and preserves b-cell mass in non-obese diabetic mice

  2012cites this paper
• Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides.

  2012cites this paper
• Immunotherapies in diabetes mellitus type 1.

  2012cites this paper
• Possible Role of GLP-1 and Its Agonists in the Treatment of Type 1 Diabetes Mellitus

  2012cites this paper
• The potential of incretin-based therapies in type 1 diabetes.

  2012cites this paper
• Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.

  2012cites this paper
• Adipose Tissue, Hormones, and Treatment of Type 1 Diabetes

  2012cites this paper
• The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.

  2012cites this paper
• Polymer-Based Delivery of Glucagon-Like Peptide-1 for the Treatment of Diabetes

  2012cites this paper
• Diabetes resolution and hyperinsulinaemia after metabolic Roux‐en‐Y gastric bypass

  2011cites this paper
• Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis

  2011cites this paper
• GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes

  2011cites this paper
• Advances in the Etiology and Management of Hyperinsulinemic Hypoglycemia After Roux-en-Y Gastric Bypass

  2011cites this paper
• Type 1 diabetes: etiology, immunology, and therapeutic strategies.

  2011cites this paper
• Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells.

  2011cites this paper
• Effects of Genetic Susceptibility for Type 2 Diabetes on the Evolution of Glucose Homeostasis Traits Before and After Diabetes Diagnosis

  2011cites this paper
• Structural study of an active analog of EX-4 in solution and micelle associated states.

  2011cites this paper
• Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology

  2011cites this paper
• Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients

  2010cites this paper
• Exenatide: A New Promising Antidiabetic Agent

  2010cites this paper
• Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area.

  2010cites this paper
• Minireview: update on incretin biology: focus on glucagon-like peptide-1.

  2010cites this paper
• Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV (DPP-IV) decreases NOD mouse CD4

  2010cites this paper
• DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes

  2010cites this paper
• Prevention of beta-cell destruction in autoimmune diabetes: current approaches and future prospects.

  2010cites this paper
• The Effect of Insulin and Insulin Resistance on Glucagon-like Peptide-1 Secretion from the Intestinal L Cell

  2010cites this paper